PepGen (NASDAQ: PEPG) — Perfil da empresa, notícias e dados financeiros
PepGen develops transformative therapies for neuromuscular diseases using its Enhanced Delivery Oligonucleotide platform.
PepGen
PepGen (NASDAQ:PEPG) is a biotechnology firm focused on the development of transformative therapies for neuromuscular and neurologic diseases. With a robust pipeline of innovative treatments, the company is dedicated to addressing some of the most challenging medical conditions, including Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy. By leveraging its cutting-edge Enhanced Delivery Oligonucleotide (EDO) platform, PepGen aims to unlock new possibilities in genetic medicine, improving the lives of patients worldwide. The company's objectives center on advancing its clinical trials, expanding its research and development efforts, and fostering partnerships to accelerate the availability of groundbreaking therapies. PepGen's commitment to science and patient care drives its pursuit of excellence and innovation in the biotech landscape.
Resumo
Operações
Produtos e/ou serviços de PepGen
- Development of enhanced delivery oligonucleotides (EDOs) for addressing neuromuscular and other severe diseases by improving cellular uptake and distribution.
- Progress on EDO51, aimed at treating Duchenne Muscular Dystrophy, focusing on skipping exon 51 to produce functional dystrophin.
- Advancement of EDO-NM for treating Myotonic Dystrophy Type 1, utilizing EDO technology to target the underlying genetic cause.
- Research on EDO-AOC, targeting Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), focusing on delivering antisense oligonucleotides to affected areas.
- Exploration of EDO-based therapies for cardiac diseases, aiming at genetic targets linked to heart function and diseases.
- Initiation of early-stage research projects targeting other genetic disorders using EDO technology, exploring broader therapeutic applications.
equipe executiva do PepGen
- James G. McArthurPresident, CEO, Treasurer, Secretary & Director
- Noel P. DonnellyChief Financial Officer
- Joseph D. VittiglioChief Business & Legal Officer and Secretary
- Kasra KasraianChief Technical Officer
- Emiko BryantSenior Vice President of HR & Administration
- Hayley ParkerSenior Vice President of Global Regulatory Affairs & Quality
- Paul D. StreckExecutive VP and Head of Research & Development
- Pallavi LonkarVice President & Head of Preclinical
- Melissa MichaelsExecutive Director & Head of Regulatory Affairs CMC
- Michael ZhaoVice President & Head of Biometrics
Principais indicadores financeiros
Resultados divulgados pela PepGen, em USD.
- Cap. de mercado
- 179,8 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -93,6 mi | -89,7 mi | |
| 0 | -97,7 mi | -90 mi | |
| 0 | -84,8 mi | -78,6 mi | |
| 0 | -68,3 mi | -69,1 mi |